نتائج البحث 201-210 من 13661 لعملية البحث عن Visceral leishmaniasis
Despite not needing therapy, these patients have significant immune dysfunction. This may lead to an increased risk of serious infections requiring ...
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in ...
This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy ...
... Cutaneous t-...cell lymphoma. إظهار المزيد من مجالات التخصص من أجل Chris L. Deufel, Ph.D. David J. DiCaudo, M.D.. Pathologist ...
The goal of this clinical research study is to learn how often breast cancer recurs (returns after treatment) in the breast in patients who have been ...
Rochester, Minn. Gastrointestinal (GI) infection with Campylobacter causes inflammation in the bowel and can change bacteria in the gut. Certain individuals ...
Given the theoretical risk of systemically re-infusing samples contaminated with tumor cells, many surgeons refrain from using intraoperative blood salvage.
Rochester, MN. مناطق التركيز: Melanoma, Cutaneous t-cell lymphoma. Rafael Fonseca, M.D.. Hematologist. Phoenix, AZ. مناطق التركيز: Bone ...
The purpose of this study is to compare the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden.
لا تُقدم Mayo Clinic الدعم للشركات أو المنتجات المُعلَّن عنها هنا. لكن تدعم العائدات الإعلانية رسالتنا غير الربحية.
تحقق من هذه الكتب الأكثر مبيعًا والعروض الخاصة على الكتب والنشرات الإخبارية من Mayo Clinic Press.
تساهم التبرّعات، وهي قابلة للخصم الضريبي، في دعم آخر التطورات في الأبحاث وطرق الرعاية لإحداث نقلة نوعية في الطب.